

90 mm

90 mm

For the use only of a Registered Veterinary Practitioner or a Hospital or a Laboratory or a Farm.



Phenylbutazone Oral Paste
StallaZON™ Oral Paste
NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
For Oral Use In Horses Only.

COMPOSITION:
Each 3 ml marking on the syringe contains:
Phenylbutazone BP 1 g
Excipients q.s.

INDICATIONS: For the relief of inflammatory conditions associated with the musculoskeletal system in horses.

DOSAGE AND ADMINISTRATION:
Horses 450 kg (1000 lb): 2 unit doses twice on day one (equivalent to 8.8 mg/kg/day), 1 unit dose twice daily for four days (i.e. 4.4 mg/kg/day), followed by 1 unit dose daily or on alternate days (i.e. 2.2 mg/kg/day), sufficient to keep the horse comfortable.
Ponies 225 kg (500 lb): 1 unit dose (i.e. 4.4 mg/kg) on alternate days.

DIRECTIONS FOR USE:
For oral use.
Before administration, adjust the syringe to the calculated dosage by setting the ring on the plunger. The paste is administered orally by inserting the nozzle of the syringe through the interdental space and depositing the required amount of the paste on the back of the tongue. The animal's mouth should be free of any food. Immediately after administration, elevate the head of the horse for a few seconds to ensure the dose is swallowed.

TARGET SPECIES:
Horses and ponies.

PHARMACOLOGICAL PROPERTIES:
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids
ATCvet-code: QM01AA01

PHARMACODYNAMIC PROPERTIES:
Phenylbutazone is a pyrazolone non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and anti-pyretic activity useful in the management of inflammatory conditions. These pharmacodynamic effects are achieved by the inhibition of prostaglandin synthetase (cyclo-oxygenase).

PHARMACOKINETIC PROPERTIES:
Phenylbutazone is generally well absorbed following oral administration. The rate, but not the extent, of absorption may be affected due to binding of phenylbutazone to food and the contents of the gastrointestinal tract. Phenylbutazone is highly bound to plasma proteins.

WARNING & PRECAUTIONS:

- Wear gloves during application.
- Wash the hands thoroughly after use.
- Do not eat, drink or smoke while handling this product.
- Do not use in horses intended for human consumption.
- Assess bodyweight as accurately as possible before calculating the dosage.
- In case of accidental eye contact, rinse immediately with plenty of water.
- In case of accidental ingestion by Human being or eye irritation, seek medical advice and show the package leaflet or label to the physician.
- Discontinue treatment if no response is evident after four to five days treatment.
- The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.

CONTRAINDICATIONS:

Do not administer to animals other than those for which it is indicated.
Hypersensitivity to any of the Ingredients.
Use with caution in patients who have a history of drug allergy.

SIDE EFFECTS:

Non-steroidal anti-inflammatory drugs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

PREGNANCY OR LACTATION:

The safety of phenylbutazone in pregnancy has not been established. Use during pregnancy should be avoided whenever possible, particularly during the first trimester.

DRUG INTERACTION:

Concurrent administration of potential nephrotoxic drugs should be avoided.
Phenylbutazone is extensively bound to plasma proteins. It may displace other drugs that are highly protein-bound e.g. some sulphonamides, warfarin or it may itself be displaced to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Phenylbutazone induces hepatic microsomal enzyme activity.

OVERDOSAGE:

Overdosing may result in gastric and large intestinal ulceration and general enteropathy.
There is no specific antidote. If signs of possible overdosage occur, treat the animal symptomatically.

WITHDRAWAL PERIODS:

Not for use in horses intended for human consumption.
Treated horses may never be slaughtered for human consumption.
The horse must have been declared as not intended for human consumption under national horse passport legislation.

Guidelines To Successful Therapy:

Use a relatively high dose for the first 48 hours, then reduce gradually to a maintenance dose. Maintain the lowest dose capable of producing desired clinical response. Response to Phenylbutazone Paste therapy is prompt, usually occurring within 24 hours. If no significant clinical effect is evident after five days, re-evaluate diagnosis and therapeutic approach. When administering Phenylbutazone Paste, the oral cavity should be empty. Deposit paste on back of tongue by depressing plunger that has been previously set to deliver the correct dose. Many chronic conditions will respond to Phenylbutazone Paste therapy, but discontinuance of treatment may result in recurrence of symptoms.

STORAGE:

Store in a cool and dry place.

PRESENTATION:

60 ml syringe packed in a Primary Carton along with the Pack Insert.

VETERINARY.

NOT FOR HUMAN USE.

FOR ANIMAL TREATMENT ONLY.

KEEP OUT OF REACH OF CHILDREN & PETS, AWAY FROM FOOD.

Carefully read the accompanying instructions before use.

Veko

Manufactured by:

Veko Care Pvt. Ltd.

Plot No. E-48 & 49, MIDC, Ranjangaon, Dist-Pune.

Maharashtra, India. Pin Code: 412220

Customer care: care@vekocare.com

TM : Trademark of Veko care



VPP1E088

120 mm

Pack Insert Printing Specifications

1.	Product	:	STALLAZON ORAL PASTE - Pack Insert		Date	:	02.01.2023
2.	Country	:	General Export (English Text)	10.	Packaging Component	:	Pack Insert Artwork
3.	No. of Colours	:	Single Color - Black	11.	Dimensions	:	90 mm x 120 mm
4.	Specification	:	60 GSM Maplitho White Paper	Folded Size : 90 mm x 30 mm			
5.	Machine Layout no.	:	NA	12.	Pack Code No.	:	VPP1E088
6.	Design/Style	:	NA	13.	Supersedes Pack Code No.	:	NA
7.	Barcode No.	:	NA	14.	Location	:	Ranjangaon
8.	Revision No.	:	NA	15.	Artist	:	Ramesh
9.	A/w File Name	:	General Export \ STALLAZON \ STALLAZON ORAL PASTE - Pack Insert				
16.	Revision History	:	NA				
Approved By:							
	MKT		RA	QC	PROD.	QA	WAREHOUSE
							NA
Date:							